Fluorescence spectroscopy for in vitro amyloid-β (Aβ) fibrillation diagnosis and spectral fluorescence signature for the identification of bioactive compounds were applied to study traditional Ayurvedic nutraceuticals – Brahmi, Ashwagandha, Shanka pushpi, and Gotu kola – as well as their plant extracts for possible treatment of Alzheimer’s disease. All samples manifest as inhibitors on three different variants of the Aβ peptide: methionine Aβ1–40, Aβ1–40, and Aβ1–42. The main compounds within the nutraceuticals were identified. Since related medicals are known to have reduced negative post- and side-effects and even may introduce further positive health impacts by preventing pathogen plaque formation and reducing free Aβ to a natural level, such treatment approaches could be of further interest.
TiimanA, NoormagiA, FriedemannM, KrishtalJ, PalumaaP, TouguV (2013) Effect of agitation on the peptide fibrillization: Alzheimer’s amyloid-beta peptide 1-42 but not amylin and insulin fibrils can grow under quiescent conditions. J Pept Sci19, 386–391.
2.
FriedemannM, HelkE, TiimanA, ZovoK, PalumaaP, TouguV (2015) Effect of methionine-35 oxidation on the aggregation of amyloid-beta peptide. Biochem Biophys Rep3, 94–99.
3.
WitterS,
WitterR,
ViluR,
SamosonA (2018) Medical plants and nutraceuticals for amyloid beta fibrillation inhibition. J Alzheimers Dis Rep2, 14.
4.
BengraineK, MarhabaTF (2003) Comparison of spectral fluorescent signatures-based models to characterize DOM in treated water samples. J Hazard Mater100, 117–130.
5.
MazinaJ, VaherM, KuhtinskajaM, PoryvkinaL, KaljurandM (2015) Fluorescence, electrophoretic and chromatographic fingerprints of herbal medicines and their comparative chemometric analysis. Talanta139, 233–246.
6.
PoryvkinaL, TsvetkovaN, SobolevI (2014) Evaluation of apple juice quality using spectral fluorescence signatures. Food Chem152, 573–577.
7.
BabichenkoS, LeebenA, PoryvkinaL, van der WagtR, de VosF (2000) Fluorescent screening of phytoplankton and organic compounds in sea water. J Environ Monit2, 378–383.
8.
DudeizakAE, BabichenkoSM, PoryvkinaLV, SaarKJ (1991) Total luminescent spectroscopy for remote laser diagnostics of natural water conditions. Appl Opt30, 453–458.
9.
HeJH, ChengYJ, HanYL, ZhangH, YangT (2008) [Investigation of quantitative detection of water quality using spectral fluorescence signature]. Guang Pu Xue Yu Guang Pu Fen Xi28, 1870–1874.
10.
ZhaoNJ, LiuWQ, CuiZC, ZhangYJ, LiuJG, LiHB, YangLS (2006) [Analysis of the characters of organic matter in water using spectral fluorescence signature and fitting Gaussian]. Guang Pu Xue Yu Guang Pu Fen Xi26, 922–924.
11.
BabichenkoS, PoryvkinaL, OrlovY, PersiatsevI, RebrikS (1998) Fluorescent Signatures in Environmental Analysis: The Encyclopedia of Environmental Analysis and Remediation.John Wiley & Sons Inc., New York.
12.
HudsonSA, EcroydH, KeeTW, CarverJA (2009) The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds. FEBS J276, 5960–5972.
NoormagiA, PrimarK, TouguV, PalumaaP (2012) Interference of low-molecular substances with the thioflavin-T fluorescence assay of amyloid fibrils. J Pept Sci18, 59–64.
15.
WolfeLS, CalabreseMF, NathA, BlahoDV, MirankerAD, XiongY (2010) Protein-induced photophysical changes to the amyloid indicator dye thioflavin T. Proc Natl Acad Sci U S A107, 16863–16868.
16.
KrebsMR, BromleyEH, DonaldAM (2005) The binding of thioflavin-T to amyloid fibrils: localisation and implications. J Struct Biol149, 30–37.
17.
HaweA, SutterM, JiskootW (2008) Extrinsic fluorescent dyes as tools for protein characterization. Pharm Res25, 1487–1499.
18.
BiancalanaM, KoideS (2010) Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta1804, 1405–1412.
19.
RaoBS, GuptaKK, KaranamP, PeruriA (2014) Alzheimer disease: An interactome of many diseases. Ann Indian Acad Neurol17, 48–54.
20.
RaoRV, DescampsO, JohnV, BredesenDE (2012) Ayurvedic medicinal plants for Alzheimer’s disease: a review. Alzheimers Res Ther4, 22.
21.
RayS, JhaS (2001) Production of withaferin A in shoot cultures of Withania somnifera. Planta Med67, 432–436.
22.
MilnerJA, RomagnoloDF (2010) Bioactive compounds and cancer, Humana Press, New York, NY.
23.
ChadwickD, MarshJ, Sathāban Wicčhai Čhulāphōn (Bangkok Thailand) (1990) Bioactive compounds from plants, John Wiley & Sons, Chichester, England; New York.
24.
Functional Food Center Inc. (2018) Bioactive compounds in health and disease. Food Science Publisher/Functional Food Center Inc., Plano, TX.
25.
GoyalMR, AyelesoAO (2018) Bioactive compounds of medicinal plants:properties and potential for human health, Apple Academic Press, Toronto; New Jersey.
26.
ScarlettCJ, VuongQV (2015) Plant bioactive compounds for pancreatic cancer prevention and treatment, Nova Publishers/Nova Science Publishers, Inc., New York.
27.
GoyalMR, JoyPP, SuleriaH (2019) Plant secondary metabolites for human health: extraction of bioactive compounds, Apple Academic Press, Palm Bay, Florida.
28.
DomínguezH, Muñoz GonzálezM (2017) Water extraction of bioactive compounds: from plants to drug development, Elsevier, Amsterdam, Netherlands
.
29.
PolyaGM (2003) Biochemical targets of plant bioactive compounds: a pharmacological reference guide to sites of action and biological effects, Taylor & Francis, London; New York.
Švarc-GajićJ (2013) Biological activity of natural products, Nova Science Publishers, Inc., Hauppauge, New York.
32.
de BeerD, PauckCE, AucampM, LiebenbergW, StiegerN, van der RijstM, JoubertE (2018) Phenolic and physicochemical stability of a functional beverage powder mixture during storage: effect of the microencapsulant inulin and food ingredients. J Sci Food Agric98, 2925–2934.
33.
WangC, PengR, WangL, ChenP, WangS, XuX, ZhangQ, LinS, HuX (2014) Wushen, a food mixture containing 55 different natural ingredients, inhibits S180 tumor growth in vivo. Food Funct5, 1475–1480.
34.
SatohH (2013) Pharmacological characteristics of Kampo medicine as a mixture of constituents and ingredients. J Integr Med11, 11–16.
35.
JouybanA, ChanHK, Barzegar-JalaliM, AcreeWEJr. (2002) A model to represent solvent effects on the chemical stability of solutes in mixed solvent systems. Int J Pharm243, 167–172.
36.
HarrisJR, FahrenholzF (2005) Alzheimer’s disease: cellular and molecular aspects of amyloid beta, Springer, New York.
37.
International Society of Amyloidosis (1994) Amyloid. Parthenon Pub., Taylor & Francis, Stony Brook, N.Y.; Philadelphia, PA.
OtzenDE (2013) Amyloid fibrils and prefibrillar aggregates: molecular and biological properties, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
40.
BudsonAE, KowallNW (2011) The handbook of Alzheimer’s disease and other dementias, Wiley-Blackwell, Chichester, West Sussex, UK.
41.
García-FruitósE (2015), Insoluble proteins: methods and protocols, Humana Press, New York.
42.
MirkinNG, KrimmS (2016) Other species in the aqueous environment of a peptide can invert its intrinsic solvated polyproline II/beta propensity: Implications for amyloid formation. Biopolymers105, 305–311.
43.
SahaA, MondalG, BiswasA, ChakrabortyI, JanaB, GhoshS (2013) In vitro reconstitution of a cell-like environment using liposomes for amyloid beta peptide aggregation and its propagation. Chem Commun (Camb)49, 6119–6121.
44.
VivekanandanS, BrenderJR, LeeSY, RamamoorthyA (2011) A partially folded structure of amyloid-beta(1-40) in an aqueous environment. Biochem Biophys Res Commun411, 312–316.
RudolphAS, WegrzynRD (2012) Alzheimer’s disease: targets for new clinical diagnostic and therapeutic strategies, CRC Press/Taylor & Francis, Boca Raton, FL.
55.
SigurdssonEM, CaleroM, GassetM (2012), Amyloid proteins: methods and protocols,
Humana Press, New York.
56.
PoschA (2015), Proteomic profiling: methods and protocols,
Humana Press, New York.
57.
(2018) Amyloid proteins: methods and protocols, Springer Science+Business Media, New York, NY.
58.
AhoL (2010) Amyloid-β deposition in the brains of subjects with cerebrovascular disease, diabetes, synucleinopathy and alcohol abuse: a human post-mortem study (thesis). Kuopio, pp. XIX, 93, 52 s.
59.
IsobeT (1988), Amyloid and amyloidosis, Plenum Press, New York.
60.
KameyamaM (1991) [Beta]-amyloid precursor proteins and neurotransmitter function: proceedings of the eighth Workshop on Neurotransmitters and Diseases, Tokyo, June 1, 1991, Excerpta Medica: Elsevier Science Pub. Co.
61.
BredesenDE (2017) The end of Alzheimer’s: the first program to prevent and reverse cognitive decline.Avery, New York.
62.
TouguV, KarafinA, ZovoK, ChungRS, HowellsC, WestAK, PalumaaP (2009) Zn(II)- and Cu(II)-induced non-fibrillar aggregates of amyloid-beta (1-42) peptide are transformed to amyloid fibrils, both spontaneously and under the influence of metal chelators. J Neurochem110, 1784–1795.
63.
ChitiF, DobsonCM (2009) Amyloid formation by globular proteins under native conditions. Nat Chem Biol5, 15–22.
64.
AguzziA, O’ConnorT (2010) Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov9, 237–248.
65.
GarveyM, TepperK, HauptC, KnupferU, KlementK, MeinhardtJ, HornU, BalbachJ, FandrichM (2011) Phosphate and HEPES buffers potently affect the fibrillation and oligomerization mechanism of Alzheimer’s A beta peptide. Biochem Biophys Res Commun409, 385–388.
66.
KilarskiWM, FuX, RoomansGM, BackstromT, UlmstenU (1995) In vitro effect of Hepes buffer on maintaining the number of gap junction plaques in human myometrium at term. Folia Histochem Cytobiol33, 151–155.
67.
LuoS, PalD, ShahSJ, KwatraD, PaturiKD, MitraAK (2010) Effect of HEPES buffer on the uptake and transport of P-glycoprotein substrates and large neutral amino acids. Mol Pharm7, 412–420.
68.
RyanTM, CaineJ, MertensHD, KirbyN, NigroJ, BreheneyK, WaddingtonLJ, StreltsovVA, CurtainC, MastersCL, RobertsBR (2013) Ammonium hydroxide treatment of Abeta produces an aggregate free solution suitable for biophysical and cell culture characterization. PeerJ1, e73.
69.
Perez-SerradillaJA, OrtizMC, SarabiaL, de CastroMD (2007) Focused microwave-assisted Soxhlet extraction of acorn oil for determination of the fatty acid profile by GC-MS. Comparison with conventional and standard methods. Anal Bioanal Chem388, 451–462.
70.
CampanellaB, PulidoriE, OnorM, PassagliaE, TegliS, IzquierdoCG, BramantiE (2016) New polymeric sorbent for the solid-phase extraction of indole-3-acetic acid from plants followed by liquid chromatography – Fluorescence detector. Microchem J128, 68–74.
71.
GodlewskaK, MichalakI, TuhyL, ChojnackaK (2016) Plant growth biostimulants based on different methods of seaweed extraction with water. Biomed Res Int2016, 5973760.
72.
PereiraC, BarrosL, FerreiraICFR (2016) Extraction, identification, fractionation and isolation of phenolic compounds in plants with hepatoprotective effects. J Sci Food Agric96, 1068–1084.
73.
SibulFS, OrcicDZ, SvircevE, Mimica-DukicNM (2016) Optimization of extraction conditions for secondary biomolecules from various plant species. Hem Ind70, 473–483.
ElangoSRaR (2011) Estimation of alkaloid content of Ashwangandha (Withania somnifera) with HPLC methods. J Exp Sci2, 39–41.
77.
KuboyamaT, TohdaC, KomatsuK (2005) Neuritic regeneration and synaptic reconstruction induced by withanolide A. Br J Pharmacol144, 961–971.
78.
BhūtyāRaKr (2011) Ayurvedic medicinal plants of India, Scientific Publishers (India), Jodhpur.
79.
MirjaliliMH, MoyanoE, BonfillM, CusidoRM, PalazonJ (2009) Steroidal lactones from Withania somnifera, an ancient plant for novel medicine. Molecules14, 2373–2393.
80.
MishraLC, SinghBB, DagenaisS (2000) Scientific basis for the therapeutic use of Withania somnifera (ashwagandha): a review. Altern Med Rev5, 334–346.
81.
SangwanNS, SabirF, MishraS, BansalS, SangwanRS (2014) Withanolides from Withania somnifera Dunal: development of cellular technology and their production. Recent Pat Biotechnol8, 25–35.
82.
ScartezziniP, SperoniE (2000) Review on some plants of Indian traditional medicine with antioxidant activity. J Ethnopharmacol71, 23–43.
NathanPJ, ClarkeJ, LloydJ, HutchisonCW, DowneyL, StoughC (2001) The acute effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy normal subjects. Hum Psychopharmacol16, 345–351.
85.
StoughC, LloydJ, ClarkeJ, DowneyLA, HutchisonCW, RodgersT, NathanPJ (2001) The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology (Berl)156, 481–484.
86.
RoodenrysS, BoothD, BulzomiS, PhippsA, MicallefC, SmokerJ (2002) Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology27, 279–281.
87.
BhowmikD, Sampath KumarKP, PaswanS, SrivatavaS, pd. YadavA, DuttaA (2012) Traditional Indian herbs Convolvulus pluricaulis and its medicinal importance. J Pharmacogn Phytochem1, 50–58.
88.
JoshiH, ParleM (2006) Brahmi rasayana improves learning and memory in mice. Evid Based Complement Alternat Med3, 79–85.
89.
ZhengCJ, QinLP (2007) Chemical components of Centella asiatica and their bioactivities. Zhong Xi Yi Jie He Xue Bao5, 348–351.
90.
KizhakkePA, OlakkaranS, AntonyA, TilagulKS, HunasanahallyPG (2019) Convolvulus pluricaulis (Shankhapushpi) ameliorates human microtubule-associated protein tau (hMAPtau) induced neurotoxicity in Alzheimer’s disease Drosophila model. J Chem Neuroanat95, 115–122.
91.
KaurM, PrakashA, KaliaAN (2016) Neuroprotective potential of antioxidant potent fractions from Convolvulus pluricaulis Chois. in 3-nitropropionic acid challenged rats. Nutr Neurosci19, 70–78.
92.
MalikJ, KaranM, VasishtK (2016) Attenuating effect of bioactive coumarins from Convolvulus pluricaulis on scopolamine-induced amnesia in mice. Nat Prod Res30, 578–582.
93.
AgarwaP, SharmaB, FatimaA, JainSK (2014) An update on Ayurvedic herb Convolvulus pluricaulis Choisy. Asian Pac J Trop Biomed4, 245–252.
94.
BihaqiSW, SinghAP, TiwariM (2012) Supplementation of Convolvulus pluricaulis attenuates scopolamine-induced increased tau and amyloid precursor protein (AbetaPP) expression in rat brain. Indian J Pharmacol44, 593–598.
95.
VermaS, SinhaR, KumarP, AminF, JainJ, TanwarS (2012) Study of Convolvulus pluricaulis for antioxidant and anticonvulsant activity. Cent Nerv Syst Agents Med Chem12, 55–59.
96.
BihaqiSW, SharmaM, SinghAP, TiwariM (2009) Neuroprotective role of Convolvulus pluricaulis on aluminium induced neurotoxicity in rat brain. J Ethnopharmacol124, 409–415.
97.
SrivastavaDN, DeshpandeSM (1975) Gas chromatographic identification of fatty acids, fatty alcohols, and hydrocarbons of Convolvulus pluricaulis (Chois). J Am Oil Chem Soc52, 318–319.
98.
MalikJ, ChoudharyS, KumarP (2015) Protective effect of Convolvulus pluricaulis standardized extract and its fractions against 3-nitropropionic acid-induced neurotoxicity in rats. Pharm Biol53, 1448–1457.
99.
KaulMK, KumarA, AhujaA, MirBA, SuriKA, QaziGN (2009) Production dynamics of Withaferin A in Withania somnifera (L.) Dunal complex. Nat Prod Res23, 1304–1311.
100.
KumarS, SinghR, GajbhiyeN, DhananiT (2018) Extraction optimization for phenolic- and Withanolide-rich fractions from Withania somnifera roots: identification and quantification of Withaferin A, 12-deoxywithastromonolide, and Withanolide A in plant materials and marketed formulations using a reversed-phase HPLC-photodiode array detection method. J AOAC Int101, 1773–1780.
101.
MirzajaniF, GhassempourA, Jalali-HeraviM, MirjaliliMH (2010) Optimisation of a microwave-assisted method for extracting withaferin A from Withania somnifera Dunal. using central composite design. Phytochem Anal21, 544–549.
102.
PatelSB, RaoNJ, HingoraniLL (2016) Safety assessment of Withania somnifera extract standardized for Withaferin A: Acute and sub-acute toxicity study. J Ayurveda Integr Med7, 30–37.
